{
    "root": "caeef7bd-39f4-4e9f-8f3c-54aaf0e9da8d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Divalproex sodium"
    },
    "value": "20250303",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        }
    ],
    "indications": "divalproex sodium delayed-release capsules anti-epileptic indicated : monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1 )",
    "contraindications": "divalproex sodium delayed-release capsules may swallowed whole contents may sprinkled soft food . drug/food mixture swallowed immediately ( avoid chewing ) ( 2.2 ) safety doses 60 mg/kg/day established ( 2.1 , 2.2 ) complex partial seizures : start 10 mg/kg/day 15 mg/kg/day , increasing 1 week intervals 5 mg/kg/day 10 mg/kg/day achieve optimal response ; response satisfactory , check valproate plasma level ; full prescribing information conversion monotherapy ( 2.1 ) absence seizures : start 15 mg/kg/day , increasing 1 week intervals 5 mg/kg/day 10 mg/kg/day seizure control limiting side effects ( 2.1 )",
    "warningsAndPrecautions": "divalproex sodium delayed-release capsules , usp ( sprinkle ) , oral 125 mg , blue transparent/white opaque size \u201c 0 \u201d hard gelatin capsules , filled white off-white colored pellets . capsules available following features , presentations : features body color white opaque body imprint 125 body imprint color black cap color blue transparent cap imprint dv cap imprint color black presentations ndc codes hdpe bottles 100 's child-resistant closure 27241-115-01 hdpe bottles 500 \u2019 27241-115-05 hdpe bottles 1000 \u2019 27241-115-10 recommended storage : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "divalproex sodium delayed-release capsules administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . divalproex sodium delayed-release capsules contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . divalproex sodium delayed-release capsules contraindicated patients known hypersensitivity [ ( 5.12 ) ] . divalproex sodium delayed-release capsules contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . prophylaxis migraine headaches : divalproex sodium delayed-release capsules contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Divalproex sodium delayed-release capsules are an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 )",
    "contraindications_original": "Divalproex sodium delayed-release capsules may be swallowed whole or the contents may be sprinkled on soft food. The drug/food mixture should be swallowed immediately (avoid chewing) ( 2.2 ) Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 ) Complex Partial Seizures: Start at 10 mg/kg/day to 15 mg/kg/day, increasing at 1 week intervals by 5 mg/kg/day to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; see full prescribing information for conversion to monotherapy ( 2.1 ) Absence Seizures: Start at 15 mg/kg/day, increasing at 1 week intervals by 5 mg/kg/day to 10 mg/kg/day until seizure control or limiting side effects ( 2.1 )",
    "warningsAndPrecautions_original": "Divalproex sodium delayed-release capsules, USP (sprinkle), for oral use 125 mg, are blue transparent/white opaque size \u201c0\u201d hard gelatin capsules, filled with white to off-white colored pellets. The capsules are available with the following features, and presentations: \n                  \n                  \n                     \n                        \n                        \n                     \n                     \n                        \n                           \n                              Features\n                              \n                           \n                        \n                        \n                           Body color\n                           \n                           White Opaque\n                           \n                        \n                        \n                           Body imprint \n                           \n                           125\n                           \n                        \n                        \n                           Body imprint color\n                           \n                           Black\n                           \n                        \n                        \n                           Cap color\n                           \n                           Blue Transparent\n                           \n                        \n                        \n                           Cap imprint \n                           \n                           DV\n                           \n                        \n                        \n                           Cap imprint color\n                           \n                           Black\n                           \n                        \n                        \n                           \n                              Presentations and NDC Codes\n                              \n                           \n                        \n                        \n                           HDPE Bottles of 100's with child-resistant closure\n                           \n                           27241-115-01\n                           \n                        \n                        \n                           HDPE Bottles of 500\u2019s\n                           \n                           27241-115-05\n                           \n                        \n                        \n                           HDPE Bottles of\u00a01000\u2019s\n                           \n                           27241-115-10\n                           \n                        \n                     \n                  \n                  Recommended Storage: Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Divalproex sodium delayed-release capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (\n                        \n                           \n                              5.1\n                           )]. \n                     Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (\n                        \n                           \n                              5.1\n                           )]. \n                     Divalproex sodium delayed-release capsules are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (\n                        \n                           \n                              5.12\n                           )]. \n                     Divalproex sodium delayed-release capsules are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (\n                        \n                           \n                              5.6\n                           )].\n                     For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release capsules are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (\n                              5.2\n                           , \n                              5.3\n                           , \n                              5.4\n                           ) and Use in Specific Populations (\n                              8.1\n                           )]."
}